{"id":"non-insulin-anti-diabetic-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Weight changes"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sanofi manufactures multiple non-insulin anti-diabetic agents across different drug classes, including sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Each class targets different pathways in glucose homeostasis to achieve glycemic control in type 2 diabetes mellitus. The specific mechanism depends on which individual agent within Sanofi's portfolio is being referenced.","oneSentence":"Non-insulin anti-diabetic treatments work through various mechanisms to lower blood glucose by enhancing insulin secretion, improving insulin sensitivity, reducing hepatic glucose production, or slowing carbohydrate absorption.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:59:02.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (multiple agents across various classes)"}]},"trialDetails":[{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT05305287","phase":"PHASE4","title":"Quantifying Hepatic Mitochondrial Fluxes in Humans","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-11-01","conditions":"Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders","enrollment":60},{"nctId":"NCT04770532","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":526},{"nctId":"NCT04460885","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-25","conditions":"Diabetes Mellitus, Type 2","enrollment":984},{"nctId":"NCT06725238","phase":"","title":"Acute-to-chronic Glycemic Ratio (ACGR) is a Marker of DFUs .","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2024-05-01","conditions":"Diabetic Foot Ulcer (DFU)","enrollment":80},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT00455858","phase":"PHASE4","title":"Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":87},{"nctId":"NCT03312478","phase":"PHASE4","title":"Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-10-13","conditions":"Type 1 Diabetes","enrollment":375},{"nctId":"NCT02874313","phase":"PHASE4","title":"CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea","status":"COMPLETED","sponsor":"Hospital Universitario La Paz","startDate":"2016-08","conditions":"Diabetic Retinopathy, Sleep Apnea","enrollment":82},{"nctId":"NCT02320721","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1014},{"nctId":"NCT02378077","phase":"NA","title":"Understanding the Relationship Between Inflammation and Insulin Resistance in the Adipose Tissue","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-08","conditions":"Obesity, Insulin Resistance","enrollment":28},{"nctId":"NCT03665350","phase":"PHASE2","title":"Insulin Treatment in Diabetic Older People With Heart Failure.","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-11-08","conditions":"Heart Failure, Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT02004366","phase":"PHASE4","title":"Linagliptin Inpatient Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":295},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT03196154","phase":"","title":"Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":255},{"nctId":"NCT02129595","phase":"NA","title":"Resveratrol and First-degree Relatives of Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2014-04","conditions":"Pre-diabetes","enrollment":15},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00537303","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":296},{"nctId":"NCT00869908","phase":"","title":"Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66726},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT00842192","phase":"","title":"An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":2155},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02898467","phase":"","title":"Atherothrombosis Markers in Diabetics","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2016-10","conditions":"Diabetes, Atherothrombosis, Cardiovascular Disease","enrollment":100},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02587741","phase":"EARLY_PHASE1","title":"Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetic Retinopathy","enrollment":600},{"nctId":"NCT00360334","phase":"PHASE3","title":"A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Type 2 Diabetes","enrollment":235},{"nctId":"NCT00741429","phase":"","title":"A 2-Month Safety Follow-Up Trial","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2007-05","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":649},{"nctId":"NCT01602913","phase":"","title":"Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12","conditions":"Depression, Postpartum","enrollment":1},{"nctId":"NCT00339833","phase":"PHASE4","title":"The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2003-03","conditions":"Type 2 Diabetes, Diabetes","enrollment":54},{"nctId":"NCT00851903","phase":"PHASE3","title":"Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 2","enrollment":112},{"nctId":"NCT00751114","phase":"PHASE4","title":"Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-11","conditions":"Diabetes Mellitus, Type 2","enrollment":515},{"nctId":"NCT00949442","phase":"PHASE4","title":"Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00668408","phase":"PHASE4","title":"LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2008-05","conditions":"Lung Diseases, Obstructive, Chronic Heart Failure, Chronic Hypoxemia","enrollment":1000},{"nctId":"NCT00147836","phase":"NA","title":"Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2004-09","conditions":"Type 2 Diabetes Mellitus","enrollment":436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Non-insulin anti-diabetic treatment","genericName":"Non-insulin anti-diabetic treatment","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-insulin anti-diabetic treatments work through various mechanisms to lower blood glucose by enhancing insulin secretion, improving insulin sensitivity, reducing hepatic glucose production, or slowing carbohydrate absorption. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}